MACK News and Press, Merrimack Pharmaceuticals Inc. From 11/09/22

MACK Stock Explodes 240%+ Overnight, Here Are 3 Penny Stocks To Watch Now Thanks to the 2022 stock market crash, there are plenty of penny stocks to watch. The broad market sell-off has taken even some of the most popular names and sent them below the $5 mark. That might be bad for ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: shutterstock.com/Champhei Merrimack Pharmaceuticals (NASDAQ: MACK ) stock is rocketing higher on Wednesday following positive clinical trial data . Ipsen , Merrimack Pharmaceuticals’ partner, ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! We’ve got earnings reports, a public o...

U.S. biotech Merrimack Pharma ( NASDAQ: MACK ) added ~183% pre-market Wednesday after its French partner for cancer therapy Onivyde, Ipsen S.A. ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) said that the drug as a combination therapy met the primary endpoint in a late-stage trial ...

Merrimack Pharmaceuticals press release ( NASDAQ: MACK ): Q3 GAAP EPS of -$0.03. As of September 30, 2022, Merrimack had cash and cash equivalents of $13.1 million, compared to $14.6 million as of September 30, 2021. For further details see: Merrimack Pharmaceuti...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2022 financial results for the period ended September 30, 2022. “During the third quarter we continued to see the benefits of reduced ...

Summary MACK has a $225m milestone if its drug Onivyde works in first-line pancreatic cancer (already approved in second-line). The stock has been badly misvalued because the vast majority of pancreatic cancer drugs are targeted therapies that fail in the clinic. But the activ...

Merrimack Pharmaceuticals is a biotech shell with substantial milestone payments potentially due to it based on the success of Ipsen's ONIVYDE drug. On August 3, 2022, Ipsen announced that one of the Phase 3 trials of ONIVYDE showed little to no incremental efficacy over alternatives....

Merrimack Pharmaceuticals press release ( NASDAQ: MACK ): Q2 GAAP EPS of -$0.04. As of June 30, 2022, Merrimack had cash and cash equivalents of $13.4 million, compared to $14.2 million as of December 31, 2021. For further details see: Merrimack Pharmaceuticals G...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2022 financial results for the period ended June 30, 2022. “We are pleased to report continued reductions in operating expenses as we...